111 related articles for article (PubMed ID: 12742818)
1. NSAIDs and hypertension.
Aisen PS; Schafer K; Grundman M; Thomas R; Thal LJ
Arch Intern Med; 2003 May; 163(9):1115; author reply 1115-6. PubMed ID: 12742818
[No Abstract] [Full Text] [Related]
2. Is rofecoxib safer than naproxen?
Adelman A
J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
[No Abstract] [Full Text] [Related]
3. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
4. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
6. Upper gastrointestinal toxicity of rofecoxib and naproxen.
Delgado Fernández M; Zambrana García JL; Diez García F
N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336056
[No Abstract] [Full Text] [Related]
7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Burgess FW; Browning RA
Med Health R I; 2001 Oct; 84(10):327-8. PubMed ID: 11693050
[No Abstract] [Full Text] [Related]
10. [Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
MMW Fortschr Med; 2003 Aug; 145(31-32):56-7. PubMed ID: 14524083
[No Abstract] [Full Text] [Related]
11. Discontinuation of Vioxx.
Nyberg J
Lancet; 2005 Jan 1-7; 365(9453):24-5; author reply 26-7. PubMed ID: 15639670
[No Abstract] [Full Text] [Related]
12. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.
Suthisisang CC; Poolsup N; Suksomboon N; Lertpipopmetha V; Tepwitukgid B
Headache; 2010 May; 50(5):808-18. PubMed ID: 20236345
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of Vioxx.
Lièvre M; Abadie E;
Lancet; 2005 Jan 1-7; 365(9453):23-4; author reply 26-7. PubMed ID: 15639668
[No Abstract] [Full Text] [Related]
14. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
[TBL] [Abstract][Full Text] [Related]
15. Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.
Anwar A; Anwar IJ; Delafontaine P
Trends Cardiovasc Med; 2015 Nov; 25(8):726-35. PubMed ID: 25956433
[TBL] [Abstract][Full Text] [Related]
16. Right ballpark, wrong base: assessing safety of NSAIDs.
Shaughnessy AF
J Fam Pract; 2002 Jun; 51(6):538. PubMed ID: 12100777
[No Abstract] [Full Text] [Related]
17. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
18. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
19. Upper gastrointestinal toxicity of rofecoxib and naproxen.
Gupta S
N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336057
[No Abstract] [Full Text] [Related]
20. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M
Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
